Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Zomig
Zolmitriptan · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Zolmitriptan | DRUG | 5mg Nasal Spray |
| Placebo | DRUG | - |
Inclusion Criteria: * Subject has an established diagnosis of migraine headache, with or without aura * Subject has a medical history indicating the presence of migraine attacks for at least 1 year before the start of the trial or a minimum of 2 and maximum of 6 migraine attacks per month on averag...
Top 5 of 8 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 13 | PHASE3 | Atogepant, Ubrogepant, MEDI0618 |
| Pfizer Inc. | PFE | 11 | PHASE3 | Rimegepant, Zavegepant |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Galcanezumab |
| Amgen Inc. | AMGN | 2 | PHASE3 | Erenumab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
Zolmitriptan is used for the treatment of migraine. It is a small molecule developed by AstraZeneca PLC under the ticker AZN and has been studied in a Phase 3 clinical program in neurology, with a completed trial enrolling 2,114 participants with migraine.
Zolmitriptan targets the serotonin receptors HTR1B and HTR1D, where it acts as an agonist. By activating these receptor subtypes, the drug is designed to produce its antimigraine effects. Both HTR1B and HTR1D are the molecular targets associated with this small molecule.
Zolmitriptan is developed by AstraZeneca PLC, which trades under the ticker AZN. The company is the sponsor associated with the drug's clinical development program in migraine, a Phase 3 effort that includes a completed trial of 2,114 participants.
Zolmitriptan is in Phase 3 clinical development for migraine. Its development program includes one completed Phase 3 trial, and no trials are currently listed as active. The drug is investigational in this dataset and is not described here as approved by the FDA.
Zolmitriptan has been studied in the Phase 3 trial NCT00617747, titled Efficacy and Tolerability of Zolmitriptan Nasal Spray. That trial is completed, enrolled 2,114 participants with migraine, was randomized, double blind, and placebo controlled, and included adults 18 years and older of all sexes.